Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 12/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NT5E | P21589 | 1/20 | 0.38 |
| ▸ | HPRT1 | P00492 | 4/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.36 |
| ▸ | TK1 | P04183 | 1/20 | 0.36 |
| ▸ | POLG | P54098 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20324724 | 0.92 | PNP (0.45) | PNPPOLBNT5EHPRT1 | |
| SCHEMBL20324565 | 0.91 | PNP (0.43) | PNPPOLBNT5EHPRT1 | |
| SCHEMBL20324643 | 0.84 | ALDH1A1 (0.45) | PNPTK1 | |
| SCHEMBL21636986 | 0.83 | ALDH1A1 (0.47) | PNPHPRT1 | |
| SCHEMBL20324650 | 0.82 | POLB (0.47) | PNPPOLBNT5ETAS1R3TAS1R1 | |
| SCHEMBL20758514 | 0.81 | POLB (0.59) | PNPPOLBNT5EHPRT1TAS1R3 | |
| SCHEMBL3894678 | 0.81 | POLB (0.59) | PNPPOLBNT5EHPRT1TAS1R3 | |
| SCHEMBL21417495 | 0.81 | POLB (0.59) | PNPPOLBNT5EHPRT1TAS1R3 | |
| SCHEMBL18837841 | 0.81 | POLB (0.59) | PNPPOLBNT5EHPRT1TAS1R3 | |
| SCHEMBL13082345 | 0.80 | PNP (0.51) | PNPPOLBHPRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020016782-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN BIOTECH, INC. (US) | 2020-01-23 | — | — | WO | disclosed |
| WO-2018118665-A1 | CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2018-06-28 | — | — | WO | disclosed |